Learn more about Gain Therapeutics here.

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next-generation allosteric therapies. Gain’s lead drug candidate, GT-02287, is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.

If suddenly, you started to shrink in size, how long would it take until you became as small as a particle of dust? Why would things look different to your eyes? And why should you stay away from these grabby things? Today, you'll be scaling down - by 1 cm every second. From human-sized, all the way to the size of a subatomic particle.

This distribution was conducted on behalf of Gain Therapeutics, Inc. (NASDAQ: GANX) and was funded by Outside The Box Capital Inc. after Underknown Inc. was engaged by Outside The Box Capital Inc. to advertise for Gain Therapeutics, Inc. (NASDAQ: GANX). For our full disclaimer, please visit: here.

Support us on Patreon: here

Get the What if book: here

Join this channel to get access to perks: here

Interested in sponsoring our episodes or collaborating? Email us: [email protected]

Our other channels:

How to Survive: here

Aperture: here

T-shirts and merch: here

Newsletter: here

What If elsewhere:

Discord: here

Whatsapp: here

Instagram: here

Twitter: here

Facebook: here

Produced by Underknown: here

Learn more about your ad choices. Visit podcastchoices.com/adchoices